CSAM-SCAM Fundamentals. Cocaine Basics. Presentation provided by David C. Marsh MD CCSAM

Similar documents
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines

Main Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?

Opioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine

The causes of misuse:

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008

Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users.

THE STATE OF MEDICINE IN ADDICTION RECOVERY

The future of pharmacological treatment.

Opioids Research to Practice

Polysubstance Use & Medication-Assisted Treatment

NALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

MARRCH Minnesota Society of Addiction Medicine Presents. Addiction as a Brain Disease

TREATMENT OF NICOTINE DEPENDENCE

Pharmacotherapy for Substance Use Disorders

Opioid dependence: Detoxification

Addiction as a Neuropsychiatric Medical Condition

BASIC VOLUME. Elements of Drug Dependence Treatment

Substitution Therapy for Opioid Use Disorder The Role of Suboxone

Neurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP

Noel Schenk MD. Davis Behavioral Health

Opioids Research to Practice

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC

Management Options for Opioid Dependence:

Models of good practice in drug treatment in Europe. Project group

Methamphetamine Abuse During Pregnancy

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Prescription Opioid Addiction

Methamphetamine & Cocaine Use Disorders

Brief Intervention for Smoking Cessation. National Training Programme

Update on Medications for Tobacco Cessation

The Importance of Psychological Treatment and Behavioral Support

Addiction Overview. Diane A. Rothon MD. Causes Consequences Treatments. Methadone/Buprenorphine 101 April 1, 2017

SW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass

Building capacity for a CHC response to Ontario's Opioid Crisis

Methamphetamine & Cocaine Use Disorders

Medication-Assisted Treatment (MAT) Overview

Medication Assisted Treatment of Substance Use Disorders

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

What are Substance Use Disorders?

LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines

Breaking the Chains of Nicotine Dependence - A Breakthrough Approach

Methamphetamine & Cocaine Use Disorders

Does the Use of Oral Amphetamines Reduce Cocaine Use in Cocaine-Dependent Individuals?

Buprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17

Biological Addictions Treatment. Psychology 470. Many Types of Approaches

DRUGS, ALCOHOL & MENTAL HEALTH, HOW THEY CONNECT

Understanding Addiction: Why Can t Those Affected Just Say No?

Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP

Understanding Addiction and Its Impact on the Brain. SDSMA Webinar Matthew Stanley, DO

OPIOID ADDICTION AND THE BRAIN MICHAEL NERNEY AND ASSOCIATES P.O. BOX 93 LONG LAKE, NY

TREATMENT OF STIMULANT USE DISORDERS

Quality assurance in pharmacotherapy with methadone

Opioids Research to Practice

Intro to Concurrent Disorders

Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services

Trigger. Myths About the Use of Medication in Recovery BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS

Vivitrol Vs. Suboxone

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

Page 1. Pharmacologic Interventions for. Addictions. Objectives for This Talk. Outline for This Talk

Pharmacologic Interventions for. Addictions

Management of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013

Opioids and Opioid Addiction: Practical Management Approaches

Long term treatment for opioid dependence Antagonist therapy

Pharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations

ADHD and Substance Use Disorders: An Intoxicating Combination

THE OPIOID CRISIS 9/19/2018 DEFINING THE CRISIS DEFINING THE CRISIS NUMBER OF OPIOID-RELATED OVERDOSE DEATHS IN ALABAMA

Evidence-Based Practice: Psychosocial Interventions

Thaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs

ROSC & MAT II: Opioid Treatment Services

National Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says

TOOL 1: QUESTIONS BY ASAM DIMENSIONS

8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy

Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry

Buprenorphine as a Treatment Option for Opioid Use Disorder

Exploring Barriers & Solutions in Facilitating Detox

9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare

Substance Use Disorders. A Major Problem. Defining Addiction 2/24/2009. Lifetime rates of alcoholism estimated at 13.4 %

Opiate Use Disorder and Opiate Overdose

The role of behavioral interventions in buprenorphine treatment of opioid use disorders

Opioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA

The Sinclair Method (TSM) for the Treatment of Alcoholism. Clinical Research Findings and Best Protocol for Success Updated 2014

Many drugs of abuse are illegal drugs. Possessing, using, buying, or selling these drugs is illegal for people of any age.

Improving Outcomes in Methadone Treatment

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT

Treatment Alternatives for Substance Use Disorders

Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations

Medical Interventions for Addiction in Primary Care Settings. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale University School of Medicine

2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders

Treatment of Methamphetamine Dependence: Does Treatment Work?

6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder

The National Methamphetamine Symposium

Mary Ann Ferguson,Pharmacist St Josephs Health Care Concurrent Disorders Inpatient Unit

Adult 65D-30 Intervention ASAM Level.05 DIMENSIONS Circle all items in each dimension that apply to the client. ADMISSION CRITERIA

Medical Management of Substance Use Disorders: Does research translate to clinical practice

Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC

Transcription:

CSAM-SCAM Fundamentals Cocaine Basics Presentation provided by David C. Marsh MD CCSAM

Chronic Illness Relapsing & Remitting in Course Genetic Predisposition Individual Choice a Factor Environmental Influence Potentially Fatal If Untreated Prevention Is Possible Properly Managed Can Lead Normal Life

Response Rates Drug and Alcohol Treatment 40-60% abstinent at 1 year (vary with drug) Best outcomes in those maintained in MMT or Participating in on-going Mutual Support Diabetes, Hypertension, Asthma 40-60% medication compliance <30% adherence with diet and risk reduction 50% symptoms require medical intervention within 1 year McLellan, Lewis, O Brien and Kleber (2000) JAMA 284:1689-1695

Cocaine Effects Blocks Catecholamine Reuptake Dopamine, Noradrenalin, Adrenaline Euphoria Increased Energy Insomnia Anorexia Hypertension and Tachycardia Often combined with Alcohol to Prolong Effect

Cocaine Problems Multiple Organ Systems Damaged By Restriction of Blood Flow and Increased Metabolic Demand Myocardial Infarct or Arrhythmias Multiple Small Cerebral Infarcts Frequently Increased Sexual Risk Behaviour Risks Associated with Route of Use Smoking/Snorting Respiratory Damage Blood-Borne Illnesses passed by Sharing Implements Injection Local Sequelae including Infections Systemic Infections (Bacterial, Fungal, Viral)

# correct in 45 sec Stroop Task Improvement During Methamphetamine Abstinence Control (n = 141) * < 72 h n = 86 3 Months n = 19 *p < 0.05

Depression In Methamphetamine Abusers 16 14 BDI Score 12 10 8 6 4 2 0 Control scores = 0-4 1 2 3 4 5 Weeks of Abstinence

Time (msec) % Correct Methamphetamine Abusers Show Impaired Attention * Reaction Time Accuracy *p<0.05

Cingulate Cortex In Methamphetamine Abuse Anterior Cingulate Posterior Cingulate

Glucose Metabolism (mg/100 g/min) Reaction Time Correlated To Angular Gyrus Metabolism In Methamphetamine Abusers CONTROL METHAMPHETAMINE r = -0.17 r = 0.92 p < 0.05 Reaction Time (msec)

Emergency Management of Intoxication Stabilize Vital Signs (ABC s) Rule Out or Treat General Medical Conditions Diabetic Coma Subdural Haematoma Seizures Pneumonia Meningitis GI Bleeding

Subacute Management of Intoxication Provide a Reality Base Use names often State location repeatedly Non-Verbal Support Frequent, brief eye contact Relaxed posture Constant Subdued Lighting Never leave alone Always Check for Pregnancy Opiate Withdrawal in pregnancy can precipitate miscarriage

Pharmacological Treatment of Withdrawal (General Approaches) Symptomatic relief Cross-tolerance with longer half-life agent Less reinforcing and less dangerous mode of delivery of drug

Withdrawal Management and Treatment Treatment of Withdrawal is Not Treatment Patients with Substance Dependence requiring withdrawal management all require treatment Outpatient Counseling Intensive Day Treatment Intensive Residential Treatment Short-Term Residential Transitional Treatment Long-Term Residential Treatment Supportive Housing

Pharmacotherapy For Continuing Care (Broad Strategies) Pharmacological Avenues Aversion Decreased Appetite Decreased Reinforcement and Extinction Relapse Prevention Antagonist maintenance Long Acting Agonist Maintenance Prevent Complications In Face of Use

Oral Amphetamine Maintenance for Cocaine Dependence Pilot Study for 14 weeks (16 Pts. 60 mg/day; 14 Placebo) Treatment retention was equivalent between group Cocaine-positive urine samples treatment group declined from 94% to 56% compared no change in the placebo group (79% positive). treatment group reduced self-reported cocaine use (P= 0.02) reduced criminal activity (P=0.04) reduced cravings (P<0.01) reduced severity of cocaine dependence (P<0.01) no within-group improvements found in the placebo group Shearer J et al (2003) Addiction 98:1137-1141

Pilot Studies of Medications for Cocaine Dependence in Heroin-Assisted Treatment Nuijten et al (2011) BMC Psychiatry 11:135

Topirimate for Cocaine Dependence Poor compliance with medication Limited benefit Nuijten et al (2015) Drug Alc Dep 138:177

Modafinil for Cocaine Dependence Poor compliance with medication Limited benefit unless high adherence Nuijten et al (2015) J Psychopharmacol 29:678

Fundamentals: Cannabis Dependence Summary Cocaine is highly reinforcing Dependence can be devastating to function but most users do not progress to dependence Treatment is challenging Relies on Psychosocial Interventions Medications should be primarily within context of clinical trials until proven effective